September 2016 Update. A busy 7 years! (14/9/16)
In our previous (2013) update we resolved to do better at updating our website more regularly – we didn’t do very well?!

But we have been very busy, so much so that in March 2015, Ros, having already reduced her toxicology workload, switched to working full time with Tim on the marketing and medical communication projects.

And very pleasingly for us, the projects we’ve secured have included some new disease areas, thus enabling us to continue to further extend our expertise, although breast cancer and general oncology remain a specialty area.

Since 2011 Pivotal 4pharma have worked on nearly 40 projects with a company specialising in KOL mapping, and have involved interviewing International Experts in a number of different disease areas. This has given us insight into very different disease areas; projects have included oncology and immuno-oncology but have also extended into other areas such as idiopathic pulmonary fibrosis (IPF), short bowel syndrome, asthma, chronic obstructive pulmonary disease, ADHD, biosimilars, lower urinary tract symptoms and benign prostatic hyperplasia/hypertrophy…to name just a few.

Much time in the past couple of years has also been spent working alongside a Medical Communications Agency in the production of several Core Value Dossiers (CVD), and specifically supporting an International Pharma company from a strategic perspective with respect to proposing new Value Propositions and Value Messages. These have been across a number of different disease areas including prostate cancer, peripheral neuropathic pain, clostridium difficile infections (CDI) and overactive bladder.

We have been also working with a Pharma company in the breast cancer disease area, the project involved the development of a comprehensive ‘Q and A’ databank to provide a resource to support the sales force in the launch stage of a new treatment for metastatic breast cancer.

We have also recently been involved in the faculty and symposia management for 2 symposia in the area of paediatric anaesthesia, at the World Congress of Anaesthesiologists (WCA) in Hong Kong and The European Society for Paediatric Anaesthesiology (ESPA) in Belgrade.

Another notable recent deliverable was a payer key value message workshop – working in collaboration with a Medical Communications agency in support of an International Pharma company. For this workshop we both developed and designed the workshop and facilitated the meeting.

In summary, a very busy last couple of years which has seen us broaden our knowledge and experience into new therapy and disease areas.

If you would like to discuss potential new projects, or find out more about the services offered by Pivotal 4pharma, please do not hesitate to contact us.